Related Experiment Video
Updated: May 17, 2026
13:37
Split-and-pool Synthesis and Characterization of Peptide Tertiary Amide Library
Published on: June 20, 2014
Drugs from slugs. Part II--conopeptide bioengineering
Jon-Paul Bingham1, Elizabeth A Andrews, Shaun M Kiyabu
1Department of Molecular Biosciences and Bioengineering, University of Hawaii, Honolulu, HI 96822, USA. jbingham@hawaii.edu
Chemico-Biological Interactions
|October 16, 2012
Summary
Bioengineering peptide toxins from Conus snails overcomes challenges in drug development. These advancements create novel research tools and potential pharmaceuticals with improved specificity and potency.
Area of Science:
- Biochemistry
- Pharmacology
- Peptide Engineering
Background:
- Transforming toxins into research probes or drug leads is challenging due to toxicity, impacting specificity, potency, and bioavailability.
- The drug development pipeline often halts progress for toxic compounds.
Purpose of the Study:
- To discuss the bioengineering of conopeptides, a class of peptide toxins from Conus snails.
- To illustrate biochemical approaches for maximizing the research and pharmaceutical potential of conopeptides.
Main Methods:
- Sequential bioengineering of conopeptides.
- Biochemical strategies to enhance biological activity and pharmaceutical value.
Main Results:
- Development of novel research probes and drug leads derived from conopeptides.
- Demonstration of successful bioengineering to improve conopeptide characteristics.
Conclusions:
- Conopeptide bioengineering offers a viable strategy to overcome toxicity and developmental hurdles.
- These engineered peptides hold significant promise for both biological research and pharmaceutical applications.
Related Concept Videos
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:30Prodrugs
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...